Elite Pharmaceuticals (OTCMKTS:ELTP) Announces Earnings Results

Elite Pharmaceuticals (OTCMKTS:ELTP) issued its quarterly earnings data on Thursday. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, Zacks reports. Elite Pharmaceuticals had a net margin of 40.19% and a return on equity of 47.99%.

Elite Pharmaceuticals Stock Performance

Shares of OTCMKTS ELTP opened at $0.31 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.45 and a quick ratio of 5.22. The firm has a market cap of $333.91 million, a price-to-earnings ratio of 7.75 and a beta of 0.40. The stock’s fifty day moving average price is $0.37 and its two-hundred day moving average price is $0.38. Elite Pharmaceuticals has a one year low of $0.27 and a one year high of $0.74.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.